Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Allergy Therapeutics ( (GB:AGY) ) has shared an update.
Allergy Therapeutics has received marketing authorization from the Paul Ehrlich Institut in Germany for its innovative subcutaneous grass pollen allergen immunotherapy, Grassmuno®. This approval marks the first of its kind under Germany’s TAV programme and is expected to significantly impact the German seasonal allergy market, projected to reach approximately US$1 billion by 2030. The approval is a pivotal moment for the company, validating its MATA MPL platform and supporting its expansion strategy into other global markets. Grassmuno® offers a convenient, short-course treatment option for grass pollen allergies, potentially driving business growth in Germany, the company’s largest market.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, specializing in the treatment and diagnosis of allergic disorders. The company focuses on aluminium-free immunotherapies with potential disease-curing capabilities and operates in nine major European countries, with additional distribution agreements in ten more countries.
Average Trading Volume: 381,569
Technical Sentiment Signal: Buy
Current Market Cap: £629.5M
For detailed information about AGY stock, go to TipRanks’ Stock Analysis page.